Asia-Pacific Insulin Infusion Pump Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 328.01 Million |
| Market Size (2029) | USD 411.70 Million |
| CAGR (2024 - 2029) | 4.65 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Asia-Pacific Insulin Infusion Pump Market Analysis
The Asia-Pacific Insulin Infusion Pumps Market size is estimated at USD 328.01 million in 2024, and is expected to reach USD 411.70 million by 2029, growing at a CAGR of 4.65% during the forecast period (2024-2029).
The conventional method of daily injections or an insulin pen can be replaced by an insulin infusion pump. Insulin infusion pumps alleviate discomfort, distribute insulin more precisely than injections, and prevent huge fluctuations in blood glucose levels. When utilizing pumps, mealtime planning is not necessary. Patients can use infusion pumps more easily as a result. Continuous subcutaneous insulin infusion is another name for insulin treatment (CSII). It is a reliable and adaptable way to administer insulin. The insulin pump has improved and is now more dependable than it ever was. Numerous technical developments have been made to CSII technology, including the incorporation of continuous glucose monitoring with the pump.
The Asia-Pacific region has witnessed a rapid increase in the number of individuals diagnosed with diabetes. This can be attributed to various factors such as sedentary lifestyles, unhealthy dietary habits, and genetic predisposition. As a result, there is a growing demand for effective and convenient diabetes management solutions, including insulin infusion pumps.
Insulin infusion pumps offer several advantages over traditional insulin delivery methods such as multiple daily injections. These pumps provide a continuous and precise delivery of insulin, mimicking the natural insulin secretion pattern of the body. This helps in achieving better glycemic control and reducing the risk of complications associated with diabetes. As awareness about the benefits of insulin infusion pumps increases, more individuals are opting for this advanced technology, thereby driving the market growth.
Furthermore, the Asia-Pacific region is witnessing rapid urbanization and economic development, leading to improved healthcare infrastructure and increased access to healthcare services. This has resulted in better diagnosis and management of diabetes, leading to a higher demand for insulin infusion pumps.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Asia-Pacific Insulin Infusion Pump Market Trends
Insulin Infusion Pump Devices Dominating the Asia-Pacific Insulin Infusion Pump Market
An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin is provided by a tube (catheter), which is attached to a thin cannula, which is inserted into the layer of fat beneath your skin, usually in the area around your stomach, by the pump, which is approximately the size of a smartphone or deck of cards and worn on the exterior of your body.
The pump can be carried in a pump case around your waist, strapped to a belt or bra, tucked into a pocket, or worn on an armband. You can have your insulin pump look stylish with specially manufactured attachments. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. An autoimmune reaction in which the body's immune system attacks the insulin-producing beta cells in the pancreas is the primary cause of type-1 diabetes.
To maintain appropriate glucose levels, patients with type-1 diabetes need daily insulin injections, usually up to four times a day. Chronic glucose levels may lead to complications such as retinopathy and nephropathy.
Insulin pump therapy is a treatment in which insulin is continuously administered using a portable pump. The insulin is delivered into the patient's body through a subcutaneously inserted cannula. Because the insulin dosage can be adjusted accurately depending on day-to-day activities such as exercise and meal choice, it is expected to improve glucose management and help prevent complications.
An insulin pump has been demonstrated in studies to enhance diabetes management and reduce the risk of hypoglycemia. When using an insulin pump, many patients find that they have more freedom in timing their meals and activities. Sharing insulin pump data with the care team between office visits allows patients to get the most out of the time they spend with them during their sessions.
Uploading pump data helps the care team track patterns and, if necessary, make changes to your care plan. Insulin pumps use short-acting and rapid-acting insulin but are not long-acting since the pump is programmed to deliver a small amount continuously to keep your blood sugar levels even. Most insurance companies cover insulin pumps.
Australia and China are Expected to Dominate the Asia-Pacific Insulin Infusion Pump Market.
Among the Asia-Pacific countries, Australia and China dominate around 56% of the total Asia-Pacific insulin infusion pump market. This is mainly due to the high prevalence of diabetes in these countries. China records the highest healthcare expenditure in the Asia-Pacific region.
Without private health insurance, insulin pumps can cost between USD 5,000 and USD 10,000 or more. Several private health insurance providers subsidize the price of an insulin pump. Insulin pump consumables such as pump sets and lines are an ongoing cost for the patient and are not usually covered by private health insurance, NDSS, or Medicare. Although the pump and its supplies (tubing, insulin cartridges, and infusion sets) remain expensive, insurance coverage has improved considerably.
Moreover, governments and healthcare organizations in the Asia-Pacific region are increasingly focusing on diabetes management and prevention programs. This includes initiatives to raise awareness about diabetes, promote early diagnosis, and provide access to affordable treatment options. As a part of these efforts, insulin infusion pumps are being recommended as an effective tool for diabetes management, further driving the market growth.
In conclusion, the rising prevalence of diabetes in the Asia-Pacific region, coupled with the advantages offered by insulin infusion pumps and supportive healthcare initiatives, is significantly contributing to the growth of the insulin infusion pump market in this region.
Therefore, owing to the factors above, the growth of the studied market is anticipated in the Asia-Pacific region.
Asia-Pacific Insulin Infusion Pump Industry Overview
The Asia-Pacific insulin infusion pumps market is consolidated by very few companies occupying the largest market share globally and especially in the Asia-Pacific region.
Asia-Pacific Insulin Infusion Pump Market Leaders
-
Medtronic
-
Ypsomed
-
Insulet
-
Roche
-
Tandem Diabetes Care
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Insulin Infusion Pump Market News
- April 2023: Medtronics has recently revealed that the MiniMed 780G system, equipped with the Guardian 4 sensor and SmartGuard technology, has received approval from the U.S. Food and Drug Administration (FDA). This significant achievement signifies the endorsement of the sole system incorporating meal detection technology that offers automatic adjustments and corrections to blood sugar levels every 5 minutes, catering to both basal (background) and bolus (mealtime) insulin requirements. Moreover, this system assists users by providing insulin to compensate for instances when they occasionally forget to administer bolus or underestimate the carbohydrate content in their meals.
- July 2022: The Albanese Government delivered 130,000 Australians with type-1 diabetes access to subsidized CGM products under the National Diabetes Services Scheme (NDSS). This was a USD 273.1 million investment over four years to support people living with type-1 diabetes, which includes expanded access to the Insulin Pump Program. The government was also following through on its promise to broaden the requirements for participation in the separate insulin pump program. A further 35 totally subsidized insulin pumps were expected to be made available each year so that young adults with type-1 diabetes between the ages of 18 and 21, who come from low-income households, may take advantage of this revolutionary technology. Up until recently, this program was only available to youth under the age of 18.
Asia-Pacific Insulin Infusion Pump Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
- 4.4 Technology
-
4.5 Porter's Five Forces Analysis
- 4.5.1 Bargaining Power of Suppliers
- 4.5.2 Bargaining Power of Consumers
- 4.5.3 Threat of New Entrants
- 4.5.4 Threat of Substitute Products and Services
- 4.5.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Technology
- 5.1.1 Tethered Insulin Pump
- 5.1.2 Tubeless Insulin Pump
-
5.2 Component
- 5.2.1 Insulin Pump Device
- 5.2.2 Insulin Pump Reservoir
- 5.2.3 Infusion Set
-
5.3 End User
- 5.3.1 Hospital/Clinics
- 5.3.2 Home/Personal
-
5.4 Geography
- 5.4.1 Japan
- 5.4.2 South Korea
- 5.4.3 China
- 5.4.4 India
- 5.4.5 Australia
- 5.4.6 Vietnam
- 5.4.7 Malaysia
- 5.4.8 Indonesia
- 5.4.9 Philippines
- 5.4.10 Thailand
- 5.4.11 Rest of Asia-Pacific
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Medtronic
- 7.1.2 Insulet
- 7.1.3 Roche
- 7.1.4 Animas
- 7.1.5 Tandem
- 7.1.6 Terumo
- 7.1.7 Ypsomed
- 7.1.8 Cellnovo
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Roche
- 7.2.2 Animas
- 7.2.3 Medtronic
- 7.2.4 Other Company Share Analyses
8. MARKET OPPORTUNITES AND FUTURE TRENDS
Asia-Pacific Insulin Infusion Pump Industry Segmentation
A tiny, automated device called an insulin pump delivers short-acting insulin continuously throughout the day. A pump also helps lower blood sugar levels by replacing several daily injections with a continuous insulin infusion. The Asia-Pacific insulin infusion pump market is segmented by insulin pumps (technology and components (insulin pump devices, insulin pump reservoirs, and infusion sets)), End user (Hospital/Clinics and Home/Personal), and geography (Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, the Philippines, Thailand, and the rest of Asia-Pacific). The report offers the value (in USD) and volume (in units) for the above segments. This report provides a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Technology | Tethered Insulin Pump |
| Tubeless Insulin Pump | |
| Component | Insulin Pump Device |
| Insulin Pump Reservoir | |
| Infusion Set | |
| End User | Hospital/Clinics |
| Home/Personal | |
| Geography | Japan |
| South Korea | |
| China | |
| India | |
| Australia | |
| Vietnam | |
| Malaysia | |
| Indonesia | |
| Philippines | |
| Thailand | |
| Rest of Asia-Pacific |
Asia-Pacific Insulin Infusion Pump Market Research FAQs
How big is the Asia-Pacific Insulin Infusion Pumps Market?
The Asia-Pacific Insulin Infusion Pumps Market size is expected to reach USD 328.01 million in 2024 and grow at a CAGR of 4.65% to reach USD 411.70 million by 2029.
What is the current Asia-Pacific Insulin Infusion Pumps Market size?
In 2024, the Asia-Pacific Insulin Infusion Pumps Market size is expected to reach USD 328.01 million.
Who are the key players in Asia-Pacific Insulin Infusion Pumps Market?
Medtronic, Ypsomed, Insulet, Roche and Tandem Diabetes Care are the major companies operating in the Asia-Pacific Insulin Infusion Pumps Market.
What years does this Asia-Pacific Insulin Infusion Pumps Market cover, and what was the market size in 2023?
In 2023, the Asia-Pacific Insulin Infusion Pumps Market size was estimated at USD 312.76 million. The report covers the Asia-Pacific Insulin Infusion Pumps Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Insulin Infusion Pumps Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Infusion Pumps Industry Report
Statistics for the 2024 APAC Infusion Pumps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Infusion Pumps analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
